Tilray | TRLY - 销售成本

金融业

USD

USD 2.1B

现金及等价物

USD 264.83M

USD 164.37M

USD 729.32M

USD 259.32M

USD 640.95M

USD -20.01M

USD 8.37M

USD 2.84K

EPS每股收益

USD -0.41

股本和储备

USD 1.58B

USD 57.47M

债务利息支出

USD 6.7M

USD 12.83M

USD 268.59M

USD 5.12B

USD -44.93M

USD 237.52M

USD -20.01M

普通股股本

USD 116.52M

11.57

USD -39.96M

USD 217.51M

销售和管理费用

USD 24.85M

USD 282.79M

贸易债权人

USD 114.5M

应收帐款人

USD 109.07M

	销售成本	更改		日
Akebia Therapeutics	USD 10.34M		441K	2025-12
Alaunos Therapeutics	USD 0		18K	2024-09
Aurora Cannabis	CAD 88.61M		30.53M	2025-12
Avita Medical	AUD 3.3M		166K	2025-12
Canopy Growth	CAD 53.08M		8.3M	2025-12
Cronos Group	USD 26.48M		2.26M	2026-03
Divis Laboratories Ltd	INR 12.39B		1.76B	2026-03
Ionis Pharmaceuticals	USD 3M		5M	2026-03
IQVIA Holdings	USD 3.08B		161M	2026-03
Knight Therapeutics	CAD 82.22M		1.03M	2025-12
Moderna	USD 955M		503M	2026-03
Organigram Holdings	CAD 56.93M		20.53M	2025-12
Organon & Co	USD 766M		21M	2025-12
Revvity	USD 323.46M		26.93M	2026-03
Tilray	USD 164.37M		8.41M	2025-09
Viatris	USD 2.36B		195.9M	2026-03
Xeris Pharmaceuticals	USD 13.66M		49K	2025-12
Zealand Pharma A/S	410K		5K	2025-06